Document is current
Any future updates will be listed below
-
Authors
Bonakdari, Hossein
Pelletier, Jean-Pierre
Blanco, Francisco J.
Rego-Pérez, Ignacio
Durán-Sotuela, Alejandro
Aitken, Dawn
Jones, Graeme
Cicuttini, Flavia
Jamshidi, Afshin
Abram, François
Martel-Pelletier, Johanne https://orcid.org/0000-0003-2618-383X
-
Funding
Funding for this research was provided by:
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre
Chair in Osteoarthritis, University of Montreal
Canada First Research Excellence Fund through TransMedTech Institute
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 20 July 2022
First Online: 12 September 2022
Declarations
:
: All Osteoarthritis Initiative (OAI) participants provided written informed consent for participation in the OAI. Ethics approval was obtained by each OAI clinical site (University of Maryland Baltimore Institutional Review Board, Ohio State University’s Biomedical Sciences Institutional Review Board, University of Pittsburgh Institutional Review Board, and Memorial Hospital of Rhode Island Institutional Review Board) and the OAI coordinating center (Committee on Human Research at University of California, San Francisco, CA, USA (47–00532)). For the TASOAC cohort, the original study was approved by the Southern Tasmanian Health and Medical Human Research Ethics Committee [#H0006488]. For both OAI and TASOAC cohorts, all patients gave their written informed consent, including permission for the use of DNA to be collected for biomarker assessment. The Institutional Ethics Committee Board of the University of Montreal Hospital Research Centre (48–9412, 20.321-YP) approved the project.
: Not applicable.
: J-P. Pelletier and J. Martel-Pelletier are shareholders in ArthroLab Inc., and F. Abram was an employee of ArthroLab Inc. The other authors declare that they have no competing interests.
